Which of the following statements about chorionic villus sampling is false?
Most common antigen involved in erythroblastosis fetalis is:
What is the best initial management option for ovarian ectopic pregnancy?
Which of the following is not associated with maternal age?
Which of the following statements is true regarding placental site trophoblastic disease?
IgM appears in fetus at what gestational age -
What is the recommended management for jaundice due to obstetric cholestasis in the third trimester?
What is the expected rate of turnover of amniotic fluid in a pregnant woman?
What is meant by 'Battledore insertion of placenta'?
Which condition is characterized by androgenesis (purely paternal genetic origin)?
Explanation: ***Is performed only in second trimester of pregnancy*** - This statement is false because **chorionic villus sampling (CVS)** is typically performed earlier in pregnancy, specifically during the **first trimester**, usually between 10 and 13 weeks of gestation. - Performing CVS only in the second trimester would negate one of its main advantages: providing earlier genetic diagnostic information than **amniocentesis**. *Is used for prenatal genetic diagnosis* - **CVS** is a primary method for **prenatal genetic diagnosis**, allowing for the detection of chromosomal abnormalities and genetic disorders. - It involves analyzing fetal cells obtained from the **chorionic villi**. *Villi are collected from chorion frondosum* - The sample for **CVS** is indeed collected from the **chorion frondosum**, which is the fetal part of the placenta containing numerous chorionic villi. - These villi are genetically identical to the fetus, making them suitable for **genetic analysis**. *Can cause limb deformities* - There is a recognized, albeit small, risk of **limb reduction defects** associated with CVS, particularly if performed very early in gestation (before 9-10 weeks). - This risk is part of the counseling provided to prospective parents considering the procedure.
Explanation: ***D antigen in Rh group*** - The **D antigen** is the most immunogenic of the Rh antigens and is responsible for the vast majority of cases of **erythroblastosis fetalis** (hemolytic disease of the fetus and newborn). - When an **Rh-negative mother** is exposed to Rh-positive fetal blood (usually during previous pregnancies or transfusions), she can form antibodies against the D antigen, which can then cross the placenta in subsequent pregnancies and attack Rh-positive fetal red blood cells. *C antigen in Rh group* - While the **C antigen** is part of the Rh blood group system, antibodies to it are much less common and typically cause less severe hemolytic disease compared to anti-D antibodies. - The C antigen is less immunogenic than the D antigen, meaning it is less likely to provoke an immune response in an Rh-negative individual. *E antigen in Rh group* - Similar to the C antigen, the **E antigen** is another Rh antigen, but antibodies against it (anti-E) are also less frequently implicated in severe erythroblastosis fetalis than anti-D. - Antibodies to E can cause hemolytic disease, but their clinical significance is usually milder than that of anti-D. *Duffy antigen* - The **Duffy antigen system** is separate from the Rh system and is known for its role in resistance to certain malarial parasites (e.g., *Plasmodium vivax*). - Although antibodies to Duffy antigens (anti-Fya, anti-Fyb) can cause **hemolytic disease of the fetus/newborn**, they are a far less common cause of erythroblastosis fetalis than antibodies to the Rh D antigen.
Explanation: ***Surgical management (laparoscopy if stable, laparotomy if unstable)*** - **Ovarian ectopic pregnancies** are best managed surgically due to the **high vascularity of the ovary** and significant risk of hemorrhage - The surgical approach is **individualized**: **laparoscopy** is preferred for hemodynamically **stable patients**, while **laparotomy** is indicated for **unstable patients** or those with suspected rupture and massive hemorrhage - Surgery allows for **definitive treatment** with ovarian wedge resection or oophorectomy while preserving fertility when possible *Medical management with methotrexate* - **Methotrexate** has been used in selected cases of ovarian ectopic pregnancy, but success rates are **lower than tubal ectopics** due to increased vascularity - The risk of **treatment failure** with subsequent rupture and hemorrhage limits its routine use - Generally reserved for very early, small, unruptured cases with low hCG levels in carefully selected patients *Expectant management with serial monitoring* - **Expectant management** is rarely appropriate for ovarian ectopic pregnancy due to the high risk of **rupture and life-threatening hemorrhage** - The **highly vascular nature** of ovarian tissue makes spontaneous resolution unpredictable and potentially dangerous - Not recommended as initial management except in rare cases with declining hCG and very small masses *Emergency laparotomy in all cases* - While surgical management is preferred, **laparotomy is not required in all cases** - Hemodynamically **stable patients** can be safely managed with **laparoscopy**, which offers faster recovery and less morbidity - **Emergency laparotomy** is reserved for hemodynamically **unstable patients** or those with signs of massive intraperitoneal hemorrhage
Explanation: ***Post maturity*** - **Post-maturity** (post-term pregnancy, >42 weeks) does NOT have a consistent or strong association with maternal age in current obstetric literature. - While some older studies suggested associations, modern evidence shows **no significant independent effect of maternal age** on post-term pregnancy rates. - Post-term pregnancy is more related to factors like **first pregnancy**, **prior post-term delivery**, and **fetal sex** (males more common). *Preterm labour* - **Preterm birth is strongly associated with maternal age**, particularly at both extremes: - **Teenage mothers** (<20 years): Increased risk due to biological immaturity and socioeconomic factors - **Advanced maternal age** (≥35 years): Increased risk due to higher rates of maternal complications (hypertension, diabetes) and placental dysfunction - This is well-established in obstetric literature and clinical guidelines. *Aneuploidy* - The risk of **aneuploidy**, particularly **Down syndrome (Trisomy 21)**, **increases dramatically with advancing maternal age**. - At age 35: ~1/350 risk; at age 40: ~1/100 risk; at age 45: ~1/30 risk - Due to age-related decline in oocyte quality causing meiotic errors during egg formation. *Hydatidiform mole* - **Gestational trophoblastic disease** (hydatidiform mole) is strongly associated with **extremes of maternal age**: - **Women >40 years**: 5-10 fold increased risk - **Teenagers**: 1.5-2 fold increased risk - Related to abnormal fertilization events more common at age extremes.
Explanation: ***It secretes human placental lactogen*** - Placental site trophoblastic tumor (PSTT) characteristically consists of intermediate trophoblasts which secrete **human placental lactogen (hPL)**. - Unlike choriocarcinoma, PSTT secretes relatively low levels of **human chorionic gonadotropin (hCG)**. *Has a highly malignant potential* - PSTT generally has a **good prognosis** if the disease is confined to the uterus, with a survival rate of over 95%. - It has a low metastatic potential compared to choriocarcinoma, with metastases occurring in only about 15% of cases. *Mainly contains syncytiotrophoblasts* - PSTT is composed predominantly of **intermediate trophoblasts** that infiltrate the myometrium, rather than syncytiotrophoblasts or cytotrophoblasts. - The distinctive feature is the proliferation of these intermediate trophoblasts at the implantation site. *The treatment of choice is hysterectomy followed by chemotherapy* - **Hysterectomy** is generally the primary treatment for PSTT confined to the uterus, and it often cures the disease. - **Chemotherapy** is usually reserved for metastatic or recurrent disease, or in cases of extensive local invasion, and is not a routine follow-up after an uncomplicated hysterectomy.
Explanation: ***20 weeks*** - The fetal immune system begins to develop around **20 weeks of gestation**, at which point the fetus starts producing its own **IgM antibodies**. - **IgM** is the first antibody isotype produced by the developing fetal **B lymphocytes** and is important for early immune responses. *10 weeks* - While some components of the immune system may start to differentiate earlier, **IgM production** at a functional level is not yet established at **10 weeks of gestation**. - At this early stage, the fetal immune system is still primarily in its **developmental phase**, with major organogenesis occurring. *30 weeks* - By **30 weeks**, the fetus has already been producing IgM for several weeks, and the immune system is more mature, capable of a more robust **antibody response**. - While **IgG** levels are significantly increasing due to maternal transfer at this stage, **IgM production** began earlier. *at birth* - At birth, a neonate has circulating **IgM antibodies**, which are indicative of prior fetal immune activation and are measurable in umbilical cord blood. - However, the initial production of **fetal IgM** occurs much earlier in gestation, not at the time of birth.
Explanation: ***Induction of labour at 38 weeks*** - **Obstetric cholestasis (Intrahepatic Cholestasis of Pregnancy)** is associated with increased risk of **stillbirth**, particularly beyond 37-38 weeks gestation. - Induction at **37-38 weeks** is recommended to balance reducing stillbirth risk while minimizing prematurity complications. - **Current practice**: Timing depends on **bile acid levels** - delivery at 37-38 weeks for bile acids >40 μmol/L, or 38-39 weeks for milder cases (19-39 μmol/L). - This option represents the standard management approach for most cases of obstetric cholestasis. *Induction of labour at 37 weeks* - Delivery at 37 weeks is also acceptable and increasingly preferred, particularly for **severe disease** (bile acids >40 μmol/L) or when there are additional risk factors. - Both 37 and 38 weeks are within the recommended window; the choice depends on **disease severity** and individual risk assessment. - This is not incorrect, but 38 weeks represents a slightly more conservative approach balancing risks. *Induction of labour at 42 weeks* - Waiting until 42 weeks significantly increases the risk of **intrauterine fetal death (IUFD)** in pregnancies complicated by obstetric cholestasis. - Prolonged exposure to **elevated bile acids** is toxic to the fetus and increases stillbirth risk, especially after 37-38 weeks. - This approach is **contraindicated** in obstetric cholestasis. *Wait for spontaneous labour* - Expectant management beyond 38 weeks is considered **unsafe** due to the unpredictable and progressive risk of **sudden intrauterine death**. - Active management with planned delivery at 37-38 weeks is the standard of care to prevent stillbirth. - Waiting for spontaneous labor exposes the fetus to unacceptable risks.
Explanation: ***500 cc/h*** - The **amniotic fluid** undergoes a rapid and continuous turnover, with approximately **500 cc/h** being exchanged through multiple pathways. - This dynamic process ensures the constant renewal of the fluid, maintaining its critical functions for fetal development and protection. *1L/hr* - A turnover rate of 1 liter per hour is **higher than the physiological range** for normal amniotic fluid dynamics. - Such a high rate would imply an **abnormal fluid exchange**, potentially leading to imbalances. *1500 cc/h* - This rate represents an **extremely high turnover**, significantly exceeding the typical physiological exchange. - Sustained rates this high are **not consistent with normal amniotic fluid physiology** and could indicate underlying pathology. *2L/h* - A turnover rate of 2 liters per hour is **dangerously high** and far beyond the normal capacity for amniotic fluid exchange. - Such a rapid turnover would be **detrimental to fetal well-being** and is not observed in healthy pregnancies.
Explanation: ***Umbilical cord attached to the margin of the placenta*** - In a **Battledore insertion**, the **umbilical cord** inserts into the **edge** or **margin** of the placenta, rather than its center. - This unusual insertion resembles a **battledore**, a type of ancient racket or paddle with a handle at its edge (similar to those used in shuttlecock games). *Placenta attached to the margin of the membranes* - This description is more consistent with a **circumvallate placenta**, where the chorionic plate is smaller than the basal plate, leading to a rolled or folded margin of placental tissue covered by membranes, but it does not describe Battledore insertion. - In circumvallate placenta, the chorionic plate's edge rolls back and is surrounded by a ring of membranes, while Battledore refers specifically to the cord's insertion. *Placenta attached to the center of the uterus* - This simply indicates a **normal location** for the placenta within the uterine cavity and does not describe any abnormal insertion of the umbilical cord or specific characteristics of the placenta itself. - The placenta typically attaches to the uterine wall and can be central, fundal, or anterior/posterior, but this statement doesn't relate to the cord's insertion point. *Umbilical cord attached to the membranes* - This condition is known as **velamentous insertion of the umbilical cord**, where the cord blood vessels fan out within the amniotic membrane before reaching the placental tissue. - Velamentous insertion is a distinct anomaly from Battledore insertion and carries different risks, such as vasa previa and a higher risk of vessel compression or rupture.
Explanation: ***Androgenic complete mole*** - A **complete hydatidiform mole** is characterized by the absence of maternal genetic material and a **purely paternal genetic origin** (androgenesis). - This typically results from the **fertilization of an 'empty' egg** by either two haploid sperm or one diploid sperm. *Turner's syndrome* - This condition is a **chromosomal disorder** in females where one of the two X chromosomes is missing or incomplete (45, X0). - It is not associated with androgenesis but rather with the **absence of a functionally complete X chromosome**. *Polycystic ovary syndrome (PCOS)* - PCOS is an **endocrine disorder** characterized by **hormonal imbalance** (high androgens), ovulatory dysfunction, and polycystic ovaries. - It involves maternal and paternal genetic contributions in a normal diploid set and is not related to androgenesis. *Androgenic partial mole* - A **partial hydatidiform mole** typically involves **triploidy**, where there are two sets of paternal chromosomes and one set of maternal chromosomes (e.g., 69, XXX or 69, XXY). - While it involves extra paternal genetic material, it is not purely paternal in origin, as a **maternal haploid set is also present**.
Fetal Assessment Techniques
Practice Questions
Hypertensive Disorders in Pregnancy
Practice Questions
Intrauterine Growth Restriction
Practice Questions
Multiple Gestation
Practice Questions
Rh Isoimmunization and Other Blood Group Incompatibilities
Practice Questions
Intrauterine Fetal Therapy
Practice Questions
Prenatal Diagnosis and Genetic Counseling
Practice Questions
Placental Abnormalities
Practice Questions
Preterm Labor and Delivery
Practice Questions
Management of Medical Disorders in Pregnancy
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free